IFNA1 and systemic lupus erythematosus: The first indications that type one interferon might play a pivotal part in SLE development in humans came from observations that patients treated with IFNα for hepatitis C [76] or malignancies [77, 78] could develop antinuclear antibodies and, in some cases, lupus-like syndromes.